BI Steps Up Efforts In China’s Cardiovascular Market
This article was originally published in PharmAsia News
Last year, Boehringer Ingelheim's prescription drug sales soared more than 40 percent to 700 million yuan in China. Cardiovascular products contributed 16 percent of the revenue and BI aims to increase the proportion to one third of its total sales. The strong confidence stems from the company's ONTARGET trial on Micardis(telmisartan), the largest global cardiovascular trial. BI first presented the results at the 2008 Annual Scientific Session of the American College of Cardiology. (Click here for more - Chinese Language)
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.